About the Company
nkarta therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. nkarta was founded on the proprietary, robust and well characterized natural killer (nk) cell expansion technology pioneered by dario campana. the company is focused on leveraging the natural potent power of nk cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. nkarta is combining its nk expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. founded in 2015, the company’s investors include sr one, nea and novo ventures. for more information, please visit the company’s website at www.nkartatx.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NKTX News
Innovative NK-Cell Therapy: A Buy Rating for Nkarta’s Groundbreaking Approach to Autoimmune Diseases
Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell therapies to treat cancer. Read More on NKTX: ...
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks
Nkarta, Inc. (NKTX) has been beaten down lately with too much selling pressure. While the stock has lost 39.3% over the past four weeks, there is light at the end of the tunnel as it is now in ...
Nkarta (NASDAQ: NKTX)
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product ...
What's Going On With Cancer Drug-Developer Nkarta Stock?
Nkarta, Inc. (NASDAQ: NKTX) shares are blasting higher Monday, and the stock has gained more than 270% over the past month. Here's a look at what's going on. What To Know: ...
Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders
Nkarta's stock soared 690% in six months, buoyed by promising cell therapy technology for cancer and autoimmune diseases. Financially healthy, with a high current ratio and a cash runway extending ...
Nkarta Inc Ordinary Shares NKTX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Nkarta to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced ...
Nkarta Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Nkarta, Inc. (NKTX) latest stock news & headlines – Yahoo Finance
Key Insights Given the large stake in the stock by institutions, Nkarta's stock price might be vulnerable to their... Nkarta, Inc. (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing ...
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, June 27 ...
Nkarta Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...